Skip Navigation


PEDS Advance Access originally published online on October 12, 2009
Protein Engineering Design and Selection 2009 22(12):723-731; doi:10.1093/protein/gzp054
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
22/12/723    most recent
gzp054v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Shen, X.
Right arrow Articles by Shen, G.-x.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shen, X.
Right arrow Articles by Shen, G.-x.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Engineering and characterization of a baculovirus-expressed mouse/human chimeric antibody against transferrin receptor

Xin Shen1,2, Gui-bin Hu3, Si-jing Jiang3, Feng-rong He1, Wei Xing1, Li Li1, Juan Yang1, Hui-fen Zhu1, Ping Lei1 and Guan-xin Shen1,4

1Department of Immunology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, People's Republic of China 2Department of Laboratory Medicine and Technology, Hubei University of Chinese Medicine, Wuhan 430065, People's Republic of China 3 Institute of Biochemistry and Molecular Biology, Hubei University, Wuhan 430062, People's Republic of China

4To whom correspondence should be addressed. E-mail: guanxin_shen{at}yahoo.com.cn

Transferrin receptor (TfR) has been explored as a target for antibody-based therapy of cancer. In the previous study, we reported a murine anti-TfR monoclonal antibody (mAb) 7579 had good anti-tumor activities in vitro. In an attempt to reduce its immunogenicity and enhance its ability to recruit immune effector mechanism in vivo, we herein developed its chimera in the baculovirus/insect cell expression system based on the mating-assisted genetically integrated cloning (MAGIC) strategy. The chimeric light and heavy chains, containing human IgG1 constant regions, were correctly processed and assembled in insect cells, and then secreted into the mediums as heterodimeric H2L2 immunoglobulins. Furthermore, analyses of antigen-binding assay and competitive binding assay indicated that the chimeric antibody possessed specificity and affinity similar to that of its parental murine antibody. Results of the antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) assay verified that the chimeric antibody could efficiently mediate ADCC and CDC against TfR-overexpressing tumor cells. These results suggested that this baculovirus-expressed chimeric anti-TfR IgG1 might have the potential to be used for cancer immunotherapy. Meanwhile, the MAGIC strategy, facilitating the rapid generation of chimeric mAbs, could be one of the efficient strategies for antibody engineering.

Keywords: antibody engineering/baculovirus-insect cell expression system/chimeric antibody/MAGIC/transferrin receptor

Received April 22, 2009; revised August 9, 2009; accepted August 10, 2009.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.